Sang Hyun Cho
Associate Director of the Institute of Tuberculosis Research, College of Pharmacy - Pharmaceutical Sciences
Research Professor, Sep. 2021 - Present, Pharmaceutical Sciences
Contact
Address:
833 S Wood St. Rm 412, Chicago, IL
Office Phone:
Email:
Related Sites:
About Heading link
Overview:
In my current role as Research Professor and Associate Director of ITR, I am responsible for the planning, execution, and coordination of several ongoing research projects related to our internal and external collaborations. From a broader perspective, I have contributed in major ways to ITR’s drug discovery workflows. The most recent areas of my focus are HTS of natural products libraries, the identification of new drug leads from chemical classes with new modes of action, as well as the development of new drug candidates.
Research Interests:
Mycobacteriology including molecular biology, recombinant vaccine development, proteomic analysis of Mycobacterium tuberculosis, high throughput screening (HTS), drug target identification, and in vitro assay development.
Teaching and Supervision Heading link
Special Projects in Pharmacogn (PMPG 565), 1/14/2019 – 5/3/2019
Selected Grants
“In vitro and In vivo Mtb Pharmacology”, National Institutes of Health., 4/1/2019 - 3/31/2024, Obligated Amount: $5148409; No Anticipated Amount Set
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2024, Obligated Amount: $8489541; Anticipated Amount: $8489541
In Vitro screening of cyclic peptides which targeting mycobacterial ClpC1, Konkuk Univ., 1/15/2018 - 12/31/2020, Obligated Amount: $141000; Anticipated Amount: $141000
“Development of anti-tuberculosis lead compounds using novel cyclic peptide targeting Mycobacterial ClpC1 through protein splicing technology, RDA, Republic of Korea., 1/1/2018 - 12/31/2020, Obligated Amount: $128175; No Anticipated Amount Set
Enhancing basic and translational TB research in northern Vietnam, National Institutes of Health., 7/1/2017 - 6/30/2022, Obligated Amount: $52396; No Anticipated Amount Set
Enhancing basic and translational TB research in northern Vietnam”, National Institutes of Health., 6/1/2017 - 2/28/2022, Obligated Amount: $651957; No Anticipated Amount Set
“In vivo - vitro profiling of Actinomycetes extracts and active compounds against ClpC1 target”, RDA, Republic of Korea., 1/1/2015 - 12/31/2017, Obligated Amount: $142668.00; No Anticipated Amount Set
TB Drug Discovery from Actinomycetes, Myongji Univ., 2/1/2013 - 12/31/2017, Obligated Amount: $252800; Anticipated Amount: $252800
TB Drug Discovery from Actinomycetes, RDA, Republic of Korea., 1/2/2013 - 12/31/2014, Obligated Amount: $101289.35; No Anticipated Amount Set
Selected Publications
Tan, Jin Yi, Augustinović, Mario, Omar, Ashraf M, Lourenzon, Vitor B, Krull, Nyssa, Lopez, Xochitl, Khin, Manead, Shetye, Gauri, Nguyen, Duc, Qader, Mallique, Nugent, Angela C, Mpofu, Enock, Williams, Camarria, Rodriguez, Jonathon, Burdette, Joanna E, Cho, Sanghyun, Franzblau, Scott G, Eustáquio, Alessandra S, Zhang, Qibin, Murphy, Brian T. (2024). Discovery of New Cyclic Lipodepsipeptide Orfamide N via Partnership with Middle School Students from the Boys and Girls Club. ACS Omega, 9, (44), 44749-44759. doi:10.1021/acsomega.4c07459.
Wang, Weihong, Lee, JunI, Roh, Eun, Shetye, Gauri, Cao, Jin, McAlpine, James, Pauli, Guido, Franzblau, Scott, Vu, Thi Hanh Nguyen, Quach, Ngoc Tung, Oh, Eunseok, Park, Kyu-Hyung, Park, Chanyoon, Cho, Youbin, Jang, Hyeseon, Han, SongJoo, Kim, Hiyoung, Cho, Sanghyun, Phi, Quyet-Tien, Kang, Heonjoong. (2024). Cavomycins A–C, Linear Oligomer Depsipeptides from an Annelid-Associated Streptomyces cavourensis. Journal of Natural Products, 87, (4), 976-983. doi:10.1021/acs.jnatprod.3c01275.
Lee, Jung-Ho, Ma, Rui, Nguyen, Linh, Khan, Shahebraj, Qader, Mallique, Mpofu, Enock, Shetye, Gauri, Krull, Nyssa K, Augustinović, Mario, Omarsdottir, Sesselja, Cho, Sanghyun, Franzblau, Scott G, Murphy, Brian T. (2023). Discovery of a New Antibiotic Demethoxytetronasin Using a Dual-Sided Agar Plate Assay (DAPA). ACS Infectious Diseases, 9, (8), 1593-1601. doi:10.1021/acsinfecdis.3c00171.
Hong, Jeongpyo, Duc, Nguyen Minh, Jeong, Byeong-Chul, Cho, Sanghyun, Shetye, Gauri, Cao, Jin, Lee, Hyun, Jeong, Cherlhyun, Lee, Hanki, Suh, Joo-Won. (2023). Identification of the inhibitory mechanism of ecumicin and rufomycin 4-7 on the proteolytic activity of Mycobacterium tuberculosis ClpC1/ClpP1/ClpP2 complex. Tuberculosis, 138, 102298. doi:10.1016/j.tube.2022.102298.
Liu, Rui, Marshall, Kate, Ma, Rui, Lien Thi Pham, Kim, Shetye, Gauri, Liu, Zhihao, Cho, Sanghyun, Jeong, Hyunyoung, Franzblau, Scott G, Moraski, Garrett C, Miller, Marvin J. (2022). Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties. Bioorganic Chemistry, 128, 106074. doi:10.1016/j.bioorg.2022.106074.
Ristroph, Kurt D, McManus, Simon A, Shetye, Gauri, Cho, Sang Hyun, Lee, Dennis, Szekely, Zoltan, Sinko, Patrick J, Franzblau, Scott G, Prud’homme, Robert K. (2022). Targeted Antitubercular Peptide Nanocarriers Prepared by Flash NanoPrecipitation with Hydrophobic Ion Pairing. Advanced Materials Technologies, 7, (11). doi:10.1002/admt.202101748.
Zhou, Bin, Shetye, Gauri, Wolf, Nina M, Chen, Shao-Nong, Qader, Mallique, Ray, G Joseph, Lankin, David C, Cho, Sanghyun, Cheng, Jinhua, Suh, Joo-Won, Franzblau, Scott G, McAlpine, James B, Pauli, Guido F. (2022). New Rufomycins from Streptomyces atratus MJM3502 Expand Anti-Mycobacterium tuberculosis Structure–Activity Relationships. Organic Letters, 24, (40), 7265-7270. doi:10.1021/acs.orglett.2c02493.
Shetye, Gauri S, Choi, Kyung Bae, Kim, Chang-Yub, Franzblau, Scott G, Cho, Sanghyun. (2021). In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 65, (8), 10.1128/aac.00282-10.1128/aac.00221. doi:10.1128/aac.00282-21.
de Souza, PC, Fernandes, GFS, Marino, LB, Ribeiro, CM, da Silva, PB, Chorilli, M, Silva, CSP, Resende, FA, Solcia, MC, de Grandis, RA, Costa, CAS, Cho, SH, Wang, Y, Franzblau, SG, dos Santos, JL, Pavan, FR. (2020). Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection. Biomedicine & Pharmacotherapy, 130, 110592. doi:10.1016/j.biopha.2020.110592.
Education
Degrees:
B.S., Konkuk University, South Korea, 1989
M.S., Konkuk University, South Korea, 1991
Ph.D, Konkuk University, South Korea, 1999
Postgraduate, University of Illinois at Chicago, United States, 2001
Postgraduate Training:
Postdoctoral Research Associate, University of Illinois at Chicago, United States, 2002